Presentations Will Provide Updates on Drug
Distribution and Safety Results
TORONTO and HOUSTON, TX, Nov. 9, 2017 /PRNewswire/ -
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:
MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology company,
today announced that Dr. Krystof
Bankiewicz, MD, PhD, Kinetics Foundation Chair in
Translational Research and Professor in Residence of Neurological
Surgery at the University of California San
Francisco, will present early results from the on-going
clinical trial of the Company's targeted immunotherapy, MDNA55, at
the 22nd Annual Meeting of the Society of Neuro-Oncology
("SNO") to be held from November 15-19,
2017 in San Francisco,
CA.
The oral and poster presentations by Dr. Bankiewicz will provide
an update on drug distribution and safety data from the MDNA55
Phase 2b clinical trial in patients with recurrent glioblastoma
(rGBM), the most common and deadly form of brain cancer.
The details of the presentations are as follows:
Title:
|
Clinical Trials of
Direct Delivery of Gliomas: Update on the MDNA55
Program
|
Date:
|
Wednesday, November
15, 2017
|
Time:
|
Oral Presentation:
10:25 – 10:45 am
|
Session:
|
The 2017 SNO-SCIDOT
Conference on Therapeutic Delivery to the Central Nervous System
(CNS)
|
Location:
|
Marriott Marquis
Hotel, San Francisco
|
Title:
|
MRI-guided
convective delivery of MDNA55, an interleukin-4 receptor targeted
immunotherapy for the treatment of recurrent
glioblastoma
|
Date:
|
Saturday, November
18, 2017
|
Time:
|
Poster Session: 5:00
PM
|
Location:
|
Marriott Marquis
Hotel, San Francisco
|
About Medicenna Therapeutics Corp.
Medicenna is a clinical stage immuno-oncology company developing
novel highly selective versions of IL-2, IL-4 and IL-13
Superkines™ and first in class Empowered
Cytokines™ (ECs). Its wholly owned subsidiary,
Houston-based Medicenna BioPharma, is specifically targeting the
Interleukin-4 Receptor (IL4R), which is over-expressed by at least
20 different types of cancer affecting more than one million new
cancer patients every year. Medicenna's lead IL4-EC, MDNA55 is
enrolling patients in a CPRIT (Cancer Prevention and Research
Institute of Texas) funded Phase
2b clinical trial for rGBM at leading brain cancer centres in the
US. MDNA55 has completed 3 clinical trials in 72 patients,
including 66 adults with rGBM, demonstrated compelling efficacy and
obtained Fast-Track and Orphan Drug status from USFDA. Unlike most
other cancer therapies, Medicenna's IL4-ECs have the potential to
purge both the tumor and the immunosuppressive tumor
microenvironment, offering a unique treatment paradigm for a large
majority of cancer patients.
For more information, please visit www.medicenna.com.
This news release contains forward-looking statements
relating to the future operations of the Company and other
statements that are not historical facts. Forward-looking
statements are often identified by terms such as "will", "may",
"should", "anticipate", "expects" and similar expressions. All
statements other than statements of historical fact, included in
this release, including, without limitation, statements regarding
future plans and objectives of the Company and others are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Important
factors that could cause actual results to differ materially from
the Company's expectations include the risks detailed in the annual
information form of the Company dated June
15, 2017 and in other filings made by the Company with the
applicable securities regulators from time to time.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to
differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements only
as expressly required by Canadian securities law.
SOURCE Medicenna Therapeutics Corp.